Literature DB >> 23105216

Early oxidative change in low density lipoproteins during progressive chronic renal failure.

M Sasikala1, C Subramanyam, B Sadasivudu.   

Abstract

Modified low density lipoproteins (LDL), including their oxidized forms, have been widely implicated in the etiology of atherosclerosis and concomitant cardiovascular disease (CVD) in chronic renal failure (CRF). The nature of events that lead to oxidative changes in LDL proteins are not clearly understood. Thus, patients suffering from CRF were grouped into mild, moderate and severe categories based on their blood urea and serum creatinine levels. Progression of CRF was accompanied not only with gradual increase in serum malondialdehyde (MDA) but also parallel increase in conjugated diene and MDA levels in LDL fractions separated from serum. Serum superoxide dismutase (SOD) activity was concurrently found to decrease, along with a decrease in high-density lipoprotein (HDL) cholesterol, during the progression of CRF. Gradual increase in the appearance of LDL oxidation products seems to accompany progressive manifestation of CRF. The results presented suggest that determination of serum MDA and SOD levels may enhance the diagnostic significance of the study of lipid profile in determining the risk for cardio vascular disease in CRF.

Entities:  

Keywords:  Chronic renal failure; Lipid peroxidation; Low density lipoproteins; Malondialdehyde; Superoxide dismutase

Year:  1999        PMID: 23105216      PMCID: PMC3453591          DOI: 10.1007/BF02867916

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  20 in total

Review 1.  Lipoproteins and atherogenesis. Current concepts.

Authors:  D Steinberg; J L Witztum
Journal:  JAMA       Date:  1990-12-19       Impact factor: 56.272

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

Review 3.  Role of oxidized low density lipoprotein in atherogenesis.

Authors:  J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

4.  Hypertriglyceridemia. A metabolic consequence of chronic renal failure.

Authors:  J D Bagdade; D Porte; E L Bierman
Journal:  N Engl J Med       Date:  1968-07-25       Impact factor: 91.245

5.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

6.  Heparin-induced release of extracellular superoxide dismutase to human blood plasma.

Authors:  K Karlsson; S L Marklund
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

7.  Lipid abnormalities in chronic renal failure.

Authors:  R Bhagwat; S P Joshi; P Salgia; A Sepaha
Journal:  Indian J Clin Biochem       Date:  1997-12

8.  Superoxide radical inhibits catalase.

Authors:  Y Kono; I Fridovich
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

9.  Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study.

Authors:  P Degoulet; M Legrain; I Réach; F Aimé; C Devriés; P Rojas; C Jacobs
Journal:  Nephron       Date:  1982       Impact factor: 2.847

Review 10.  Molecular therapies for vascular diseases.

Authors:  G H Gibbons; V J Dzau
Journal:  Science       Date:  1996-05-03       Impact factor: 47.728

View more
  3 in total

1.  Plasma oxidant-antioxidant status in different respiratory disorders.

Authors:  Raghunath R Rai; Madhavi S Phadke
Journal:  Indian J Clin Biochem       Date:  2006-09

2.  Antioxidant status in patients with acute myocardial infarction.

Authors:  Neela Patil; Vishwas Chavan; N D Karnik
Journal:  Indian J Clin Biochem       Date:  2007-03

3.  Dynamic changes of early-stage aortic lipid deposition in chronic renal failure rats and effects of decorin gene therapy.

Authors:  Hong-Bo Ma; Rong Wang; Ke-Zhou Yu; Che Yu
Journal:  Exp Ther Med       Date:  2014-12-04       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.